MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis Pharmaceuticals, LLC announced today that the company has licensed a third treatment for Dry Eye Syndrome (DES) now designated ARG103. This is a continuance of the licensing partnership arGentis has with the Southern College of Optometry (SCO) and becomes the third prospective therapy for DES that utilizes the transdermal delivery of an active pharmaceutical ingredient to affected glands via application of a cream or gel to the outer, upper and lower eyelids.
